Vögeli T A, Grimm M O, Simon X, Ackermann R
Urologische Klinik, Heinrich-Heine-Universität, Moorenstrasse 5, 40225 Düsseldorf.
Urologe A. 2002 Sep;41(5):470-4. doi: 10.1007/s00120-001-0158-y.
To assess the rate of residual cancer after transurethral resection (TUR) of superficial bladder cancer, a prospective study was carried out. All patients with transitional cell cancer (TCC) stage pTa-pT1 underwent a repeat TUR (ReTUR) within 6-8 weeks. Sites and rates of tumors found during ReTUR were documented as well as the morbidity of the ReTUR. Of a total of 192 TUR, superficial TCC was found in 124 cases; 83 underwent ReTUR according to the study protocol. Residual tumor was detected in 27% of pTa and 53% of pT1 tumors. Worsening of grading or T stage was found in 8%. Of the tumors detected by ReTUR, 81% were localized at the site of the first TUR. In this prospective study, residual tumor formation was detected in a high percentage. Routine ReTUR is therefore recommended in superficial bladder cancer except solitary pTaGI lesions.
为评估浅表性膀胱癌经尿道切除术（TUR）后残余癌的发生率，开展了一项前瞻性研究。所有pTa-pT1期移行细胞癌（TCC）患者在6-8周内接受了再次经尿道切除术（ReTUR）。记录了ReTUR期间发现肿瘤的部位和发生率以及ReTUR的发病率。在总共192例TUR中，124例发现浅表性TCC；根据研究方案，83例接受了ReTUR。pTa期肿瘤残余率为27%，pT1期肿瘤残余率为53%。8%的病例出现分级或T分期恶化。ReTUR检测到的肿瘤中，81%位于首次TUR的部位。在这项前瞻性研究中，残余肿瘤形成的比例较高。因此，除孤立性pTaG1病变外，建议对浅表性膀胱癌常规进行ReTUR。
